Ensitrelvir(S-217622) CAS:2647530-73-0December 3, 2022
3-(Chloromethyl)-1-methyl-1H-1,2,4-triazole hydrochloride is used as Ensitrelvir (S-217622) Intermediates. Ensitrelvir (S-217622) is an oral antiviral drug, which acts as an orally active 3C-like protease inhibitor for the treatment of COVID-19 infection. It has demonstrated antiviral effectiveness against Delta variant and the recently emerged Omicron variant. APICDMO can provide CDMO services for COVID-19 drugs with sufficient capacity, only for research use.
|Appearance||White to off-white powder||Purity||>96%|
|Application||For research use only||Storage||Store at -20°C.|
|COA & NMR||Download||MSDS||Download|
Other Ensitrelvir (S-217622) Intermediates:
6-(Ethylthio)-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-1-[(2,4,5- trifluorophenyl)methyl]-1 ,3,5-triazine-2,4(1H,3H)-dione
 Yuto Unoh, et al. Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19. bioRxiv 2022.01.26.477782.
 World Health Organization (2022). “International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 88”. WHO Drug Information. 36 (3): 89. hdl:10665/363551
 “Shionogi presents positive Ph II/III results for COVID-19 antiviral S-217622”. thepharmaletter.com. 31 January 2022.